Intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis B patient with acute exacerbation

Lin, Chien‐Chu; Wang, Ping-Huai

doi:10.1016/j.jfma.2012.08.012

Cited by 10 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GLY acts as an anti-inflammatory, anti-oxidant and immune-regulator and can protect hepatocytes. As a chronic hepatitis drug, GLY has been used in clinical practice for many years with good therapeutic effects (12,48). Previous studies have shown that GLY could exert a good effect on alcoholic liver disease (49), non-alcoholic fatty liver disease (50), intrahepatic cholestasis (51), metabolic syndrome-induced liver damage (52), acute liver injury (53), liver fibrosis (11) and hepatocellular carcinoma (54).…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that GLY has anti-oxidative, anti-inflammatory, anti-virus activities, as well as anti-fibrotic activity in the liver, and that GLY can inhibit tumor growth and enhance immunity (8–11). GLY is a natural antioxidant that has a protective effect on the liver and is widely used in the treatment of chronic hepatitis (12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress

et al. 2019

View full text Add to dashboard Cite

The present study aimed to investigate the anti-ferroptosis effects of the HMGB1 inhibitor glycyrrhizin (GLY). The present study used a cell and animal model of acute liver failure (ALF), induced using tumor necrosis factor-α, lipopolysaccharide and D-galactosamine, to investigate the effects of GLY. The expression of glutathione peroxidase 4 (GPX4) and high mobility group protein B1 (HMGB1), heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2) were detected were detected by western blotting in L02 hepatocytes and mouse liver. The expression of GPX4 and HMGB1 in L02 hepatocytes and mouse liver was detected by immunofluorescence. The pathological changes to liver tissues were determined by hematoxylin and eosin staining. The levels of lactate dehydrogenase (LDH), Fe2+, reactive oxygen species (ROS) and glutathione (GSH) were tested using kits. Compared with the normal group, the degree of liver damage and liver function in the model animal group was severe. The protein levels of HMGB1 in L02 cells and liver tissues were significantly increased. The expression of NRF2, HO-1 and GPX4 was significantly decreased. The levels of LDH, Fe2+, malondialdehyde (MDA) and ROS were increased, whereas the level of GSH was decreased. Treatment with GLY reduced the degree of liver damage, the expression of HMGB1 was decreased, and the levels of Nrf2, HO-1 and GPX4 were increased. The levels of LDH, Fe2+, MDA, ROS were decreased, while the level of GSH was increased by GLY treatment. The results of the present study indicated that HMGB1 is involved in the process of ferroptosis. The HMGB1 inhibitor GLY significantly reduced the degree of ferroptosis during ALF by inhibiting oxidative stress.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress

et al. 2019

View full text Add to dashboard Cite

show abstract

“…GR and GA were then employed in clinical practice to treat liver diseases, notably chronic viral hepatitis. A pharmacological formulation called Stronger Neo-Minophagen C (SNMC), containing 0.2% (4 mg) GA as the main active constituent, 2% (40 mg) glycine, and 0.1% (2 mg) cysteine in 20 mL ampules, was developed and has been widely used in Japan and throughout East Asia over the past 30 years to treat chronic hepatitis B or C and cirrhosis (Table 2) [33][34][35]42]. Its use in the rest of the world is more restricted [33].…”

Section: Antiviral Effectsmentioning

confidence: 99%

Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?

et al. 2021

View full text Add to dashboard Cite

The phytotherapeutic properties of Glycyrrhiza glabra (licorice) extract are mainly attributed to glycyrrhizin (GR) and glycyrrhetinic acid (GA). Among their possible pharmacological actions, the ability to act against viruses belonging to different families, including SARS coronavirus, is particularly important. With the COVID-19 emergency and the urgent need for compounds to counteract the pandemic, the antiviral properties of GR and GA, as pure substances or as components of licorice extract, attracted attention in the last year and supported the launch of two clinical trials. In silico docking studies reported that GR and GA may directly interact with the key players in viral internalization and replication such as angiotensin-converting enzyme 2 (ACE2), spike protein, the host transmembrane serine protease 2, and 3-chymotrypsin-like cysteine protease. In vitro data indicated that GR can interfere with virus entry by directly interacting with ACE2 and spike, with a nonspecific effect on cell and viral membranes. Additional anti-inflammatory and antioxidant effects of GR cannot be excluded. These multiple activities of GR and licorice extract are critically re-assessed in this review, and their possible role against the spread of the SARS-CoV-2 and the features of COVID-19 disease is discussed.

show abstract

“…All patients received glycyrrhizin treatment during hospitalization as it has been demonstrated to rapidly improve serum transaminases in AE patients [ 17 ]. Before treatment, all patients were informed of the advantages and disadvantages of receiving pegIFN, ETV, or LDT.…”

Section: Methodsmentioning

confidence: 99%

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation

Lin

Wang

et al. 2017

Gastroenterol Res

View full text Add to dashboard Cite

BackgroundThe aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE).MethodsTreatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (ETV) or telbivudine (LDT)) therapies were retrospectively selected. The HBeAg seroconversion rate, hepatitis B surface antigen (HBsAg) loss rate and the cost-effectiveness of different treatments were compared.ResultsA total of 63 patients with pegIFN therapy and 78 with NA (38 with ETV and 40 with LDT) therapy were included. The HBsAg loss rate was significantly higher in the pegIFN group when compared with the NA group (on week 96: 9/63 (14.29%) vs. 1/78 (1.28%), P = 0.005). No significant difference in hepatitis B virus (HBV) DNA negativity or the HBeAg/HBsAg seroconversion rate was found between ETV and LDT group. One year of pegIFN therapy resulted in 18.56 quality-adjusted life years (QALYs) per patient, and the incremental cost per additional QALY gained was $3,709.ConclusionsPegIFN therapy is safe in HBeAg-positive CHB patients with mild AE, as it results in a higher HBsAg loss rate and longer QALYs than NA therapy.

show abstract

Intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis B patient with acute exacerbation

Cited by 10 publications

References 3 publications

Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress

Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress

Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation

Contact Info

Product

Resources

About